Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of Recombinant Nonavalent HPV Vaccine in Healthy Chinese Women
NCT05680454Phase 1Completed
- Sponsor
- Beijing Health Guard Biotechnology Inc.
- Start
- Sep 2019
- Primary completion
- Apr 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KLWS-V502 in human papillomavirus infection (6 arms), sponsored by Beijing Health Guard Biotechnology Inc. Primary endpoint: Percentage of adverse reaction(s) within 7 days post any dose. Started Sep 2019; status: completed.
02
Drugs
KLWS-V502
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT05680454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05680454.